A case-control study on immunologic markers of patients with vitiligo
Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure select...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222201174X |
| _version_ | 1811221074186076160 |
|---|---|
| author | Barbara Nieradko-Iwanicka Daria Przybylska Andrzej Borzęcki |
| author_facet | Barbara Nieradko-Iwanicka Daria Przybylska Andrzej Borzęcki |
| author_sort | Barbara Nieradko-Iwanicka |
| collection | DOAJ |
| description | Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure selected cytokines in the blood sera of patients with vitiligo and to select the best marker of the disease. The study was conducted on 50 patients with vitiligo and 38 controls. The type of vitiligo, body surface area (BSA), disease advancement assessment according to Vitiligo European Task Force, the degree of skin involvement and degree of progression were measured. Patients' skin phototype was determined according to Fitzpatrick’s classification. Medical history was recorded. Venous blood samples were obtained, The sera were used for laboratory test. Determinations of IL-17, IL-22 and IL-23 were performed using the enzyme-linked immunoabsorbent assay. In the study group 4 cases had phototype I, 38 II, 8 III. In the control group: 3, 29, 6, respectively. Universal vitiligo was found in 38 patients, segmental in 2, acro-facial in 10. In all cases VETF was + 1. Hypothyroidism was recorded in the medical histories of 11 cases vs 2 controls. Significantly higher concentrations of IL-22 and IL-23 were in cases vs controls. IL-22 concentrations were significantly higher in the study group with BSA ≤ 10 than in the control group, and in the group with BSA ≥ 10 they were the highest (p < 0.05). IL-22 is the best marker of active universal type vitiligo, it is directly proportional to the extent of lesions. |
| first_indexed | 2024-04-12T07:53:16Z |
| format | Article |
| id | doaj.art-8b08adc8079b41c5b69e68bc23c23037 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-12T07:53:16Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-8b08adc8079b41c5b69e68bc23c230372022-12-22T03:41:33ZengElsevierBiomedicine & Pharmacotherapy0753-33222022-12-01156113785A case-control study on immunologic markers of patients with vitiligoBarbara Nieradko-Iwanicka0Daria Przybylska1Andrzej Borzęcki2Department of Hygiene and Epidemiology, Medical University of Lublin, Poland; Corresponding author.Department of Dermatology, Venerology and Pediatric Dermatology, Independent Public Healthcare Unit No.1 in Lublin, PolandDepartment of Hygiene and Epidemiology, Medical University of Lublin, PolandVitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure selected cytokines in the blood sera of patients with vitiligo and to select the best marker of the disease. The study was conducted on 50 patients with vitiligo and 38 controls. The type of vitiligo, body surface area (BSA), disease advancement assessment according to Vitiligo European Task Force, the degree of skin involvement and degree of progression were measured. Patients' skin phototype was determined according to Fitzpatrick’s classification. Medical history was recorded. Venous blood samples were obtained, The sera were used for laboratory test. Determinations of IL-17, IL-22 and IL-23 were performed using the enzyme-linked immunoabsorbent assay. In the study group 4 cases had phototype I, 38 II, 8 III. In the control group: 3, 29, 6, respectively. Universal vitiligo was found in 38 patients, segmental in 2, acro-facial in 10. In all cases VETF was + 1. Hypothyroidism was recorded in the medical histories of 11 cases vs 2 controls. Significantly higher concentrations of IL-22 and IL-23 were in cases vs controls. IL-22 concentrations were significantly higher in the study group with BSA ≤ 10 than in the control group, and in the group with BSA ≥ 10 they were the highest (p < 0.05). IL-22 is the best marker of active universal type vitiligo, it is directly proportional to the extent of lesions.http://www.sciencedirect.com/science/article/pii/S075333222201174XVitiligoInterleukin 17Interleukin 22Interleukin 23 |
| spellingShingle | Barbara Nieradko-Iwanicka Daria Przybylska Andrzej Borzęcki A case-control study on immunologic markers of patients with vitiligo Biomedicine & Pharmacotherapy Vitiligo Interleukin 17 Interleukin 22 Interleukin 23 |
| title | A case-control study on immunologic markers of patients with vitiligo |
| title_full | A case-control study on immunologic markers of patients with vitiligo |
| title_fullStr | A case-control study on immunologic markers of patients with vitiligo |
| title_full_unstemmed | A case-control study on immunologic markers of patients with vitiligo |
| title_short | A case-control study on immunologic markers of patients with vitiligo |
| title_sort | case control study on immunologic markers of patients with vitiligo |
| topic | Vitiligo Interleukin 17 Interleukin 22 Interleukin 23 |
| url | http://www.sciencedirect.com/science/article/pii/S075333222201174X |
| work_keys_str_mv | AT barbaranieradkoiwanicka acasecontrolstudyonimmunologicmarkersofpatientswithvitiligo AT dariaprzybylska acasecontrolstudyonimmunologicmarkersofpatientswithvitiligo AT andrzejborzecki acasecontrolstudyonimmunologicmarkersofpatientswithvitiligo AT barbaranieradkoiwanicka casecontrolstudyonimmunologicmarkersofpatientswithvitiligo AT dariaprzybylska casecontrolstudyonimmunologicmarkersofpatientswithvitiligo AT andrzejborzecki casecontrolstudyonimmunologicmarkersofpatientswithvitiligo |